补益肺肾加减方联合β_(2)受体激动剂对支气管哮喘的治疗效果及肺功能影响

Therapeutic effect of the BuyiFeishen decoction combined with a β_(2)receptor agonist on asthma and its influence on lung function

目的探讨补益肺肾加减方联合β_(2)受体激动剂对支气管哮喘(以下简称哮喘)的治疗效果及肺功能影响。方法选取新乡医学院第一附属医院2019年12月至2020年12月收治的78例哮喘患者作为研究对象,根据随机数字表法分为两组,每组39例。给予对照组常规糖皮质激素治疗,观察组在对照组治疗基础上应用补益肺肾加减方联合β_(2)受体激动剂治疗。对两组治疗前和治疗4周后的血氧分压(oxygen partial pressure,PaO_(2))、血二氧化碳分压(carbon dioxide partial pressure,PaCO_(2))、氧饱和度(oxygen saturation,SaO_(2))水平和肺功能水平进行比较。结果观察组的治疗总有效率为94.87%,显著高于对照组的79.49%,差异有统计学的意义(P<0.05)。两组患者治疗前PaO_(2)、PaCO_(2)、SaO_(2)指标比较,差异无统计学意义(P>0.05);治疗后观察组PaO_(2)、SaO_(2)水平高于对照组,PaCO_(2)水平低于对照组,差异有统计学的意义(P<0.05)。治疗前两组肺一氧化碳弥散量(carbon monoxide diffusing capacity,DLCO)、残气容积与总肺容积比(residual volume/total lung capacity,RV/TLV)以及第1秒用力呼气容积与用力肺活量比(forced expiratory volume in one second/forced vital capacity,FEV1/FVC)指标比较,差异无统计学意义(P>0.05);治疗后观察组DL-CO、FEV1/FVC显著高于对照组,RV/TLV显著低于对照组,差异有统计学意义(P<0.05)。治疗前两组精神健康、情感职能、社会功能、活力、躯体疼痛、生理职能、生理功能、总体健康相关生活质量评分比较,差异无统计学意义(P>0.05);治疗后观察组生活质量评分明显高于对照组,差异有统计学的意义(P<0.05)。治疗期间,观察组的不良反应发生率为17.95%,与对照组的25.64%比较,差异无统计学意义(P>0.05)。结论对哮喘患者在常规止咳平喘、抗感染、糖皮质激素等常规治疗基础上,应用补益肺肾加减方联合β_(2)受体激动剂中西医结合方式进行治疗,能够减轻患者的临床症状,减少发作频率,提升治疗效果,而且能够有效改善患者肺功能,提升患者生活质量,且不会增加不良反应,安全性较好。

Objective To determine the therapeutic effect of the BuyiFeishen decoction combined with aβ_(2)receptor agonist on asthma and its influence on lung function.Methods Seventy-eight patients with asthma treated at the First Affiliated Hospital of Xinxiang Medical College from December 2019 to December2020 were enrolled in the current study and divided into two groups based on a random number table(39 patients in each group).Patients in the control group were administered conventional glucocorticoid treatment,while patients in the observation group were treated with the BuyiFeishen decoction formula combined with aβ_(2)receptor agonist on the basis of the treatment in the control group.The blood oxygen partial pressure(PaO_(2)),blood carbon dioxide partial pressure(PaCO_(2)),and oxygen saturation(SaO_(2))levels and lung function were compared in the 2 groups before treatment and 4 weeks after treatment.Results The total effective treatment rate in the observation group was 94.87%,which was significantly higher than the total effective rate of 79.49%in the control group(P<0.05).There was no statistically significant difference in the PaO_(2),PaCO_(2),and SaO_(2)between the two groups before treatment(P>0.05).After treatment,the PaO_(2)and SaO_(2)levels in the observation group were higher than the control group,and the PaCO_(2)level was lower than the control group(P<0.05).There was no statistically significant difference in the DLCO,RV/TLV,and FEV1/FVC between the two groups before treatment(P>0.05).After treatment,the DL-CO and FEV1/FVC in the observation group were significantly higher than the control group,and the RV/TLV was significantly lower than the control group(P<0.05).There was no statistically significant difference in the mental health,emotional function,social function,vitality,physical pain,physiologic function,and overall health-related quality of life scores between the two groups before treatment(P>0.05).After treatment,the quality of life score in the observation group was significantly higher than the control group(P<0.05).During treatment,the incidence of adverse reactions in the observation group was17.95%,which was lower than the 25.64%in the control group;the difference was not statistically significant(P>0.05).Conclusion On the basis of conventional treatment,such as cough and asthma relief,anti-microbials,and glucocorticoids,administration of the BuyiFeishen decoction combined with aβ_(2)receptor agonist in the treatment of asthma improved the quality of life,reduced the clinical symptoms,reduced the frequency of attacks,improved the treatment effect,and improved lung function.BuyiFeishen decoction does not increase adverse reactions and the safety is good.